The natural history of hypertrophic cardiomyopathy (HCM) varies from an asymptomatic and benign clinical course to sudden premature death. Therefore, the new markers are searched with the aim to detect risk patients and improve their prognosis. The aim of this study was to test a cardiac multimarker testing strategy in detection of initial structural changes in patients with nonobstructive hypertrophic cardiomyopathy (HCM). In the group of 47 patients with nonobstructive HCM (58.4 ± 12.4 years, 12 emales) the mean left ventricle mass was 344.8 ± 129.9 g, the mean left ventricle mass index was 171.4 ± 60.2 g.m -2 . We observed increased concentration of cardiac markers in peripheral blood: high sensitivity troponin T (hsTnT): median: 9 ng/L (IQR: 5 -16 ng/L), vs. controls: 7 (5 -9) ng/L, p 0.03; creatine kinase MB isoenzyme (CK MB): 2 (1.4 -2.7) µg/L vs. 1.6 (1.1 -2.2) µg/L, p 0.04; myoglobin 46.4 (33.3 -65.2) µg/L vs. 35.6 (22.8 -43.7) µg/L, p 0.001; heart type of fatty acid binding protein (hFABP): 1.8 (1.4 -3.3) µg/L vs. 1.6 (1.3 -2.1) µg/L, p 0.05; glycogen phosphorylase BB (GPBB): 3.9 (2.5 -6.3) µg/L vs. 2.3 (1.9 -4.2) µg/L, p 0.001. The analysis of the associations of left ventricle mass index and cardiac markers revealed its significant association with hFABP (r = 0.41, 95% CI: 0.07-0.66, p 0.01), CKMB (r = 0.33, 95% CI: 0.11-0.59, p 0.05), and with hsTnT (r = 0.39, 95%CI: 0.12 -0.62, p 0.008). This study indicates potential clinical use of the multimarker testing in diagnosis and screening of the hypertrophic cardiomyopathy.
INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is a heterogeneous myocardial disorder characterized by myocardial hypertrophy with structural and functional abnormalities. The incidence of HCM is approximately 1 in 500 (0.2 %) of the general population (1) .
The clinical outcome of HCM is diverse, ranging from asymptomatic patients to cardiac arrhythmias, congestive heart failure, and sudden cardiac death. Patients with HCM require lifelong follow-up to detect changes in symptoms, risk of adverse events, left ventricle outflow tract obstruction (LVOTO), LV function and cardiac rhythm (1, 2) . There is a broad spectrum of biomarkers in peripheral blood, which are potentially useful for diagnosis and risk stratification in patients with HCM. But, only cardiac troponins and natriuretic peptides have the most robust data (3) (4) (5) . The association of myocardial hypertrophy, cardiac troponin and natriuretic peptide levels is not specific for the degree of left ventricle remodeling in HCM (6) (7) (8) . The increase of these parameters is probably driven more by myocardial damage or pressure overload in patients with obstructive type of LV hypertrophy and not by hypertrophy per se (9, 10) . Therefore, new markers or multimarker testing is performed with the aim to detect even initial structural changes of the myocardium (5, 11) . Because of these facts, we performed the study with the aim to use multimarker testing strategy in detection of the initial structural changes in patients with nonobstructive hypertrophic cardiomyopathy.
SUBJECTS AND METHODS

Study population
Study population consisted of patients with nonobstructive hypertrophic cardiomyopathy. The diagnosis of hypertrophic cardiomyopathy was based on history of illness, physical examination, echocardiography, and cardiac catheterization in accordance with European Society of Cardiology recommendations (2 
Assessment of cardiac markers
Blood samples were obtained from venous catheters, introduced into tube collectors containing no preservatives. Within 1 h, the blood samples were centrifuged for 10 min at 2500g and the supernatant was removed and kept at -70°C until the assay was performed.
Cardiac troponin T was measured by highsensitivity electrochemiluminiscence imunoassay using the Troponin T hs STAT assay for Elecsys 2010 analyser (Roche Diagnostics, Mannheim, Germany). The hs-cTnT assay had an analytical range from 3 to 10 000 ng/L. The cut-off value according to the manufacturer was 14 ng/L (the 99 th percentile of healthy reference population values, n = 616, CV = 9.0%).
Plasma concentrations of cardiac markers were determined by the Evidence Investigator protein biochip system (Randox Laboratories, Crumlin, UK). The cardiac array included the following markers: creatine kinase MB isoenzyme (CKMB), myoglobin (MYO), glycogenphosphorylase BB isoenzyme (GPBB), and heart type of fatty acid binding protein (hFABP). Concentrations of all cardiac markers are given in μg/L. The assay analytical parametersanalytical range, cut-off value were as follows: 
Echocardiography
Echocardiography was performed in agreement with the American Society of Echocardiography and European Association of Cardiovascular Imaging standards evaluating the following parameters: left ventricular end-diastolic (LVEDD) and end-systolic (LVESD) diameters, left atrium diameter (LA), right ventricle diameter (RV), end-diastolic interventricular septum (IVST) and posterior wall thickness (PWT), LV ejection fraction (LV EF), left ventricle fractional shortening (FS), left ventricle mass (LVM) and left ventricle mass index (LVMI) (12) . Left ventricle outflow tract gradient was evaluated in accordance with European Society of Cardiology guidelines at rest and after provocation by Valsalva maneuver [2] . For estimation of the left ventricle mass, we used formula: 0.8 x {1.04 [(LVID + PWT + IVST)3-(LVID) 3 ]} + 0.6 g, where LVID is left ventricular internal diastolic diameter, PWT is posterior wall thickness, and IVST means interventricular septal thickness diameter in diastole. 
Statistics
RESULTS
In patients with non-obstructive hypertrophic cardiomyopathy, all plasma cardiac markers were increased when compared with the control group. In patients with HCM, plasma high sensitivity troponin T level was significantly increased [median: 9 ng/L, IQR: 5 -16 ng/L, vs. median: 7 ng/L, IQR: 5 -9 ng/L, p 0.03]. Also other parameters were significantly increased ( Table 2) .
All patients underwent two-dimensional and Doppler echocardiography. Table 3 shows the summary information of echocardiographic parameters of patients with hypertrophic cardiomyopathy. The mean of the anteroposterior left atrium dimension was 48. The analysis of the associations of left ventricle mass index and cardiac markers revealed its significant association with hFABP (r = 0.41, 95% CI: 0.07 -0.66, p 0.01), CKMB (r = 0.33, 95% CI: 0.11 -0.59, p 0.05), and with hsTnT (r = 0.39, 95% CI: 0.12 -0.62, p 0.008) ( Table 4 , Fig. 1-3 
DISCUSSION
Hypertrophic cardiomyopathy is an autosomal dominant inherited myocardial disease defined by the presence of increased left ventricular wall thickness that is not solely explained by abnormal loading conditions (2) . Therefore, genetic screening is an important part of the diagnostic procedure and patient relatives follow up. According to the guidelines, HCM is inherited as an autosomal dominant genetic trait with a 50% risk of transmission to off springs. Some cases are explained by de novo mutations, but apparently sporadic cases can arise because of incomplete penetrance in a parent and, less commonly, autosomal recessive inheritance. In patients fulfilling HCM diagnostic criteria, sequencing of sarcomere protein genes identifies a disease-causing mutation in up to 60% of cases (1, 2) . The likelihood of finding a causal mutation is highest in patients with familial disease and lowest in older patients and individuals with non-classical features. But, the lack of robust data on genotype-phenotype associations means that the impact of genetic testing on clinical management is limited mostly to some of the rare genetic causes of HCM. Because of this, clinical follow up of all patient relatives is recommended. It includes regular clinical, electrocardiography and echocardiography examination. Therefore, the new strategies for detection of early stages of myocardial hypertrophy are investigated. One of the methods to detect the early myocardial structural changes is the use of multimarker strategy (3, 5, 6) .
In our study, we analyzed simultaneous assessment of cardiac markers which can reflect structural changes of myocardium. Troponins (T and I) and CK isoenzyme MB (CK-MB) are the gold standards for diagnosis of myocardial injury (3, 13) . Recently, a heart type of fatty acid binding protein (hFABP) and glycogen phosphorylase isoenzyme BB (GPBB) have been evaluated as new markers of myocardial injury (3). hFABP is a novel small cytosolic protein that is abundant in the heart, and is released into the circulation following myocardial ischemia and necrosis (13) . GPBB is a key enzyme of glycogenolysis. Its degree of association with the sarcoplasmatic reticulum glycogenolysis complex depends essentially on the metabolic state of the myocardium. With the onset of tissue hypoxia, GPBB is converted from a structurally bound into a cytoplasmatic form and released into circulation (14) . All these markers seem to be promising in detection of the structural changes of myocardium. In our study, all markers were increased in patients with nonobstructive hypertrophic cardiomyopathy. The fact that these markers were tested in patients without left ventricle obstruction is very important because it reflects that these markers are increased as a result of myocardial hypertrophy and not as a result of pressure overload caused by left ventricle tract obstruction.
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CONCLUSION
This study showed that plasma concentrations of cardiac markers (hsTnT, hFABP, GPBB, CKMB and myoglobin) are increased in patients with hypertrophic cardiomyopathy. Furthermore, this increase is present even in the absence of left ventricle tract obstruction. This study indicates potential clinical use of the multimarker testing in diagnosis and screening of the hypertrophic cardiomyopathy.
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